1. Wasilwa A, Amadi E, Ramadhani HO, Lascko T, et al.
   Impact of enhanced adherence counselling on viral re-suppression among adolescents and young persons with persistent viremia.
   AIDS 2024.
   


2. Zhang M, Dai G, Smith DL, Zacco E, et al.
   Interferon signaling pathways are upregulated in people with hiv with abnormal pulmonary diffusing capacity (DLCO).
   AIDS 2024.
   


3. Mccabe L, Burns JE, Latifoltojar A, Post FA, et al.
   MAVMET trial: maraviroc and/or metformin for metabolic dysfunction-associated fatty liver disease(MAFLD) in adults with suppressed HIV.
   AIDS 2024.
   


4. Chitle P, Sheira LA, Katabaro E, Winters S, et al.
   The Impact of Financial Incentives on Mental Health among Adults in HIV Care in Lake Zone, Tanzania: A Two-Arm Randomized Controlled Trial.
   AIDS 2024.
   


5. Zhao J, Zhou X, Qiu Y, Jia R, et al.
   Characterization of the gut butyrate-producing bacteria and lipid metabolism in African green monkey as a natural host of SIV infection.
   AIDS 2024.
   


6. .
   Albumin, white blood cell count, and body mass index improve discrimination of mortality in HIV-positive individuals: Erratum.
   AIDS 2024;38:1280.
   


7. .
   Decay of coronavirus disease 2019 mRNA vaccine-induced immunity in people with HIV: Erratum.
   AIDS 2024;38:1279.
   


8. de S Carvalho R, Rangel IC, Ferry FRA.
   Towards a refined understanding of cerebrospinal fluid CXCL13 in neurosyphilis diagnosis among people with HIV.
   AIDS 2024;38:1275-1278.
   


9. Trunfio M, Bonora S, di Perri G, Calcagno A, et al.
   Further considerations on the use of cerebrospinal fluid C-X-C motif chemokine ligand 13 in the diagnosis of neurosyphilis among people with HIV.
   AIDS 2024;38:1273-1275.
   


10. Karabay O.
    Concerns and clarifications regarding the article 'Virological, weight, and drug resistance outcomes among patients initiating a dolutegravir-based first line ART regimen in Zimbabwe'.
    AIDS 2024;38:1273.
    


11. Leroy P, Diamantis S, Sellier PO, Hamet G, et al.
    Prescriptions of generic antiretroviral drugs in three healthcare centers in the Paris area, France.
    AIDS 2024;38:1269-1272.
    


12. Rubenstein E, Diemer M, Goldwirt L, Lascoux-Combe C, et al.
    Low cabotegravir trough concentrations without oral lead-in in patients with HIV-1 switching to long-acting cabotegravir and rilpivirine.
    AIDS 2024;38:1267-1269.
    


13. Abdel-Hameed EA, Masenga SK.
    HIV-related gut damage persists long-term in perinatally acquired HIV and is associated with insulin resistance.
    AIDS 2024;38:1265-1266.
    


14. Winslow DL.
    Is early initiation of antiretroviral therapy important?
    AIDS 2024;38:1263-1264.
    


15. Moolla H, Davies MA, Davies C, Euvrard J, et al.
    The effect of care interruptions on mortality in adults resuming antiretroviral therapy.
    AIDS 2024;38:1198-1205.
    


16. Njuguna C, Long L, Mistri P, Chetty-Makkan C, et al.
    A randomised trial of "Fresh Start" text messaging to improve return to care in people living with HIV who missed appointments in South Africa.
    AIDS 2024.
    


17. Wagner TA, Tierney C, Huang S, Nichols S, et al.
    Prevalence of detectable HIV-DNA and -RNA in cerebrospinal fluid of youth with perinatal HIV and impaired cognition on antiretroviral therapy.
    AIDS 2024.
    


18. Smith AC, Goulet JL, Vlahov D, Justice AC, et al.
    Self-injurious unnatural death among Veterans with HIV: a nested case-control study.
    AIDS 2024.
    


19. Mainella V, Morrow M, Brooks K, Bushman L, et al.
    Intracellular Islatravir-Triphosphate in Dried Blood Spots and Peripheral Blood Mononuclear Cells from Pig-Tailed Macaques.
    AIDS Res Hum Retroviruses 2024;40:227-230.
    


20. Gao Y, Zhan Y, Sun Y, Zheng W, et al.
    Efficacy of Voluntary Medical Male Circumcision to Prevent HIV Infection Among Men Who Have Sex With Men : A Randomized Controlled Trial.
    Ann Intern Med 2024.
    


21. Alexandre M, Prague M, Lhomme E, Lelievre JD, et al.
    Definition of Virological Endpoints Improving the Design of Human Immunodeficiency Virus (HIV) Cure Strategies Using Analytical Antiretroviral Treatment Interruption.
    Clin Infect Dis 2024.
    


22. Weddle A.
    Position of the Infectious Diseases Society of America and the HIV Medicine Association on Team-Based Infectious Diseases Care and the Roles of Advanced Practice Providers and Clinical Pharmacists.
    Clin Infect Dis 2024.
    


23. Harris E.
    CDC Warns of Surge in Meningococcal Disease in US.
    JAMA 2024;331:1614.
    


24. Kankaka EN, Poon AFY, Quinn TC, Chang LW, et al.
    Impact of variable sampling on estimates of HIV-1 reservoir formation dates.
    J Infect Dis 2024.
    


25. Durstenfeld MS, Wilson MP, Jankowski CM, Ditzenberger GL, et al.
    Chronotropic Incompetence among People with HIV Improves with Exercise Training in the Exercise for Healthy Aging Study.
    J Infect Dis 2024.
    


26. Springer YP, Tompkins ML, Newell K, Jones M, et al.
    Characterizing the etiology of recurrent tuberculosis using whole genome sequencing-Alaska, USA, 2008-2020.
    J Infect Dis 2024.
    


27. Nazziwa J, Andrews SM, Hou MM, Bruhn CAW, et al.
    Higher HIV-1 evolutionary rate is associated with cytotoxic T lymphocyte escape mutations in infants.
    J Virol 2024.
    


28. Lewnard JA, Charani E, Gleason A, Hsu LY, et al.
    Burden of bacterial antimicrobial resistance in low-income and middle-income countries avertible by existing interventions: an evidence review and modelling analysis.
    Lancet 2024.
    


29. Mendelson M, Lewnard JA, Sharland M, Cook A, et al.
    Ensuring progress on sustainable access to effective antibiotics at the 2024 UN General Assembly: a target-based approach.
    Lancet 2024.
    


30. Jaffar S.
    Integrated HIV, diabetes, and hypertension care in sub-Saharan Africa - Authors' reply.
    Lancet 2024;403:2292.
    


31. Cai S, Xu Z, Zhao Y, Zuhlke L, et al.
    Integrated HIV, diabetes, and hypertension care in sub-Saharan Africa.
    Lancet 2024;403:2291.
    


32. Havlir D, Kamya MR, Petersen M.
    Integrated HIV, diabetes, and hypertension care in sub-Saharan Africa.
    Lancet 2024;403:2291-2292.
    


33. Maertens GN, Purcell DFJ, Rosadas C, Bradshaw D, et al.
    Why not eliminate HTLV-1 while eliminating HIV-1?
    Lancet 2024;403:2288-2289.
    

Display articles in

• Abstract format